Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MEDIWOUND TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, AUGUST 13 AT 8:30 A.M. EASTERN TIME YAVNE, ISRAEL, JULY 29, 2026 -- MEDIWOUND LTD.

MEDIWOUND TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS

ESCHAREX  PHASE III VALUE TRIAL ADVANCING; INTERIM ASSESSMENT AND ENROLLMENT COMPLETION EXPECTED BY THE END OF THE FIRST QUARTER OF 2027 FIRST QUARTER REVENUE OF $1.5 MILLION; FULL-YEAR 2026 REVENUE GUIDANCE REAFFIRMED AT $24-26 MILLION CONFERENCE CALL TODAY, MAY 27, 2026, AT 8:30 A.M. EASTERN TIME YAVNE, ISRAEL, MAY 27, 2026 (GLOBE NEWSWIRE) -- MEDIWOUND LTD.

MEDIWOUND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MEDIWOUND TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, MAY 27 TH AT 8:30 A.M. EASTERN TIME YAVNE, ISRAEL, MAY 7, 2026 -- MEDIWOUND LTD.

MEDIWOUND TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS

NEWLY PUBLISHED U.S. EXPERT CONSENSUS ALIGNS WITH MEDIWOUND'S STRATEGY FOR CHRONIC WOUND DEBRIDEMENT PEER-REVIEWED CONSENSUS REDEFINES DEBRIDEMENT FROM SIMPLE TISSUE REMOVAL TO A MORE COMPREHENSIVE BIOLOGICALLY ACTIVE DRIVER OF WOUND HEALING PANEL SUPPORTS EARLY USE OF EFFECTIVE, LESS INVASIVE TREATMENTS IN CHRONIC WOUND CARE, REINFORCING THE COMMERCIAL THESIS FOR ESCHAREX  IN CHRONIC WOUND CARE YAVNE, ISRAEL, APRIL 13, 2026  MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY HIGHLIGHTED THE PUBLICATION OF A PEER-REVIEWED SUPPLEMENT IN WOUNDS TITLED TOWARD A PRACTICAL FRAMEWORK FOR DEBRIDEMENT IN CHRONIC WOUNDS: FINDINGS FROM A UNITED STATES-BASED MULTIDISCIPLINARY CONSENSUS PANEL.

NEWLY PUBLISHED U.S. EXPERT CONSENSUS ALIGNS WITH MEDIWOUND'S STRATEGY FOR CHRONIC WOUND DEBRIDEMENT

MEDIWOUND TO PRESENT NEW ESCHAREX  DATA AT LEADING WOUND CARE CONFERENCES DATA HIGHLIGHTS MECHANISM OF ACTION, OUTCOMES IN VLUS AND DFUS, AND COMPARATIVE ADVANTAGES OVER SANTYL  FINDINGS SUPPORT ONGOING VALUE PHASE III STUDY AND PLANNED EXPANSION INTO DFUS AND PRESSURE ULCERS YAVNE, ISRAEL, APRIL 7, 2026 (GLOBE NEWSWIRE)  MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY ANNOUNCED MULTIPLE ORAL AND POSTER PRESENTATIONS AT THREE LEADING WOUND CARE CONFERENCES: THE WOUND HEALING SOCIETY (WHS) AND THE SYMPOSIUM ON ADVANCED WOUND CARE (SAWC) SPRING 2026, TAKING PLACE APRIL 812 IN CHARLOTTE, NORTH CAROLINA, AND THE EUROPEAN WOUND MANAGEMENT ASSOCIATION (EWMA) 2026, TAKING PLACE MAY 68 IN BREMEN, GERMANY.

MEDIWOUND TO PRESENT NEW ESCHAREX DATA AT LEADING WOUND CARE CONFERENCES

MEDIWOUND REPORTS BARDA CONTRACT AWARD TO VERICEL FOR NEXOBRID  VALUED AT UP TO $197 MILLION YAVNE, ISRAEL, APRIL 2, 2026  MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOCUSED ON NON-SURGICAL TISSUE REPAIR, TODAY ANNOUNCED THAT VERICEL CORPORATION (NASDAQ:VCEL), ITS EXCLUSIVE DISTRIBUTOR OF NEXOBRID IN NORTH AMERICA, HAS BEEN AWARDED A TEN-YEAR CONTRACT VALUED AT UP TO $197 MILLION BY THE U.S. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), PART OF THE ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE (ASPR) WITHIN THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS).

MEDIWOUND REPORTS BARDA CONTRACT AWARD TO VERICEL FOR NEXOBRID VALUED AT UP TO $197 MILLION

MEDIWOUND FILES ANNUAL REPORT ON FORM 20-F YAVNE, ISRAEL, MARCH 5 , 202 6 -- MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, T ODAY ANNOUNCED THAT IT HAS FILED ITS ANNUAL REPORT ON FORM 20-F FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE SEC) ON MARCH 5, 2026.

MEDIWOUND FILES ANNUAL REPORT ON FORM 20-F

ESCHAREX  PHASE III VALUE TRIAL ADVANCING AS PLANNED EXPANDED NEXOBRID  MANUFACTURING FACILITY OPERATIONAL ; REGULATORY APPROVALS EXPECTED IN 2026 $17 MILLION REVENUE IN 2025 ; $54 MILLION IN CASH AT YEAR-END; 20262028 REVENUE GUIDANCE REAFFIRMED CONFERENCE CALL TODAY, MARCH 5 , 202 6 , A T 8:30 A . M . EASTERN TIME YAVNE, ISRAEL, MARCH 05, 2026 (GLOBE NEWSWIRE) -- MEDIWOUND LTD.

MEDIWOUND REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

MEDIWOUND TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, MARCH 5 TH AT 8:30 A.M. EASTERN TIME YAVNE, ISRAEL, FEBRUARY 19, 2026 -- MEDIWOUND LTD.

MEDIWOUND TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

MEDIWOUND TO PRESENT AT UPCOMING INVESTOR CONFERENCES YAVNE, ISRAEL, FEBRUARY 17 , 2026 -- MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM WILL PRESENT AT THE FOLLOWING UPCOMING INVESTOR CONFERENCES : OPPENHEIMER 36TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE DATE: THURSDAY, FEBRUARY 26, 2026 TIME: 10:40 A.

MediWound Ltd.

MDWD

Price

Financial Reports

No items found.

Press Releases

MediWound Ltd.

MDWD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MDWD